Broderick Brian C Lowers stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Broderick Brian C reduced its stake in AbbVie Inc by 0.56% during the most recent quarter end. The investment management company now holds a total of 31,335 shares of AbbVie Inc which is valued at $2,097,878 after selling 175 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.AbbVie Inc makes up approximately 0.86% of Broderick Brian C’s portfolio.

Other Hedge Funds, Including , Finemark National Bank Trust reduced its stake in ABBV by selling 1,034 shares or 1.99% in the most recent quarter. The Hedge Fund company now holds 50,975 shares of ABBV which is valued at $3,412,776. AbbVie Inc makes up approx 0.37% of Finemark National Bank Trust’s portfolio.Ngam Advisors reduced its stake in ABBV by selling 23,297 shares or 7.06% in the most recent quarter. The Hedge Fund company now holds 306,749 shares of ABBV which is valued at $20,420,281. AbbVie Inc makes up approx 0.27% of Ngam Advisors’s portfolio. Highstreet Asset Management added ABBV to its portfolio by purchasing 11,073 company shares during the most recent quarter which is valued at $706,568. AbbVie Inc makes up approx 0.24% of Highstreet Asset Management’s portfolio.Eagle Ridge Investment Management boosted its stake in ABBV in the latest quarter, The investment management firm added 145 additional shares and now holds a total of 79,504 shares of AbbVie Inc which is valued at $5,073,150. AbbVie Inc makes up approx 1.13% of Eagle Ridge Investment Management’s portfolio.

AbbVie Inc opened for trading at $67.47 and hit $68.1239 on the upside on Monday, eventually ending the session at $67.39, with a gain of 0.30% or 0.2 points. The heightened volatility saw the trading volume jump to 52,15,360 shares. Company has a market cap of $109,747 M.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.